Recordati stock holds steady as investors look to recent earnings

Published on 09/06/2026 at 15:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Recordati stock is trading in a tight range on Piazza Affari as investors weigh the latest earnings profile and market capitalization figures against the broader Italian equity backdrop.

Moderne Pharma-Produktionsanlage mit Edelstahltanks und Glasfassade bei Tageslicht — Recordati S.p.A. (IT0003828271) betreibt moderne Pharma-Produktionsanlagen mit hochwertiger Fertigungstechnik am Firmensitz in Mailand, Italien, Illustration mit AI erstellt.

Recordati stock (ISIN IT0003828271) is currently trading in a narrow band on its home market in Milan, with recent quotes around the low-50-euro range as of September 5, 2026 according to Italian market data, leaving the share below its 52-week high but comfortably above its 52-week low on Tradegate in Germany.

Recent earnings frame the valuation

The Milan-based pharmaceutical group Recordati S.p.A. is valued in the billions of euros on Piazza Affari, with investors interpreting this market capitalization against the latest available annual and interim results that show solid revenue and profit generation in its prescription and consumer-health portfolios.

According to Italian equity classifications that rank companies by capitalization at the close of the previous trading day, Recordati sits among the larger healthcare names on the Milan exchange, underlining how its earnings power and cash flows have translated into a sizeable equity value as of September 5, 2026.

Market data: price range and capitalization

Market data compiled from European trading venues show that Recordati stock recently changed hands around 52.65 euros on the Tradegate platform, compared with a previous close of 52.75 euros and a modest daily gain of 0.29 percent as of August 13, 2026, while the 52-week high and low on that venue are reported at 54.90 euros and 43.84 euros respectively.

For investors, this positioning means the current price level is only about 4 percent below the 52-week high on Tradegate and more than 20 percent above the 52-week low, a range that suggests the stock has held relatively firm in recent months despite sector volatility and shifting interest-rate expectations in Europe.

Go deeper

More Recordati stock coverage

Read further reports and regulatory filings related to Recordati to better understand how earnings trends and guidance interact with the current share price.

All news on Recordati Investor Relations

Key products support revenue base

Recordati generates its revenue from a range of pharmaceutical brands, including vascular and circulation therapies such as Ginkor Fresh Gel, which is marketed in Europe as a topical product for relieving tired or heavy legs, reflecting the group’s presence in over-the-counter and prescription segments that contribute to its top line.

Stock level for retail investors

Based on the latest available Tradegate data, Recordati stock traded at 52.65 euros as of August 13, 2026, with that closing price sitting between the documented 52-week low of 43.84 euros and the 52-week high of 54.90 euros, all in euros, giving retail investors a concrete price frame when considering the Italian healthcare group’s shares.